1. A 38-year-old male physician with MDD has been on sertraline 200 mg for ten weeks. His mood has improved substantially and his social withdrawal has resolved, but he continues to have significant fatigue, difficulty concentrating during clinical work, and loss of motivation that he describes as "going through the motions." He has no residual anxiety, no insomnia, and no suicidal ideation. He asks about adding a medication to address his remaining symptoms. Which of the following augmentation strategies is most pharmacologically appropriate for his specific residual symptom profile?
A) Add quetiapine 50 mg at bedtime, because its 5-HT2A antagonism will disinhibit dopaminergic release in the prefrontal cortex and its sedating properties will improve sleep quality, thereby indirectly resolving the fatigue
B) Add bupropion 150–300 mg daily, because its inhibition of the norepinephrine reuptake transporter (NET) and dopamine reuptake transporter (DAT) directly targets the noradrenergic and dopaminergic deficits underlying fatigue, cognitive dysfunction, and motivational loss — the precise pharmacological dimensions that sertraline's serotonin-selective mechanism does not address
C) Add lithium 300 mg twice daily, because second-messenger potentiation of the existing serotonergic response from sertraline will amplify the partial improvement already achieved and resolve the remaining symptom burden through enhanced serotonergic neurotransmission
D) Add aripiprazole 2 mg daily, because its D2 partial agonism is the most evidence-based augmentation option for any residual symptom pattern after SSRI partial response, regardless of which specific symptom dimensions remain
E) Increase sertraline to 250 mg daily, because the residual symptoms represent insufficient serotonin reuptake blockade that will respond to further dose escalation beyond the current maximum labeled dose
ANSWER: B
Rationale:
Option B is correct. The pharmacological gap framework requires matching the augmenting agent to the neurotransmitter deficits underlying the specific residual symptom pattern. This patient's residual profile — fatigue, cognitive difficulty, and motivational loss without anxiety or insomnia — maps directly onto insufficient noradrenergic and dopaminergic activity in the prefrontal cortex and mesolimbic circuits. Sertraline's highly selective serotonin reuptake inhibition increases synaptic serotonin but exerts minimal direct effect on norepinephrine or dopamine availability. Bupropion's dual NET and DAT inhibition fills this pharmacological gap precisely: it raises norepinephrine in prefrontal circuits governing alertness and executive function, and raises dopamine in prefrontal and mesolimbic circuits mediating motivation and reward processing — the exact neurotransmitter systems corresponding to his residual symptoms. This mechanistic complementarity represents one of the most rational and commonly used augmentation combinations in clinical practice, validated in STAR*D Step 2.
Option A: Option A is incorrect because quetiapine's primary augmentation strengths are H1-mediated sedation addressing insomnia, and 5-HT2A and 5-HT1A activity addressing anxiety — neither of which is a residual symptom in this patient; its sedating properties would likely worsen his fatigue rather than resolve it.
Option C: Option C is incorrect because lithium augments primarily through serotonergic second-messenger potentiation; this patient's residual symptoms are noradrenergic and dopaminergic in character, and adding more serotonergic enhancement does not address the pharmacological gap.
Option D: Option D is incorrect because while aripiprazole has broad augmentation evidence, the pharmacological gap principle calls for mechanistic specificity; bupropion's direct NET/DAT inhibition is a more targeted fit for this patient's specific residual profile than aripiprazole's partial agonist mechanism.
Option E: Option E is incorrect because 200 mg is the maximum labeled dose of sertraline; dose escalation beyond this threshold is outside the approved labeling and is not the appropriate next step when an adequate-dose trial has produced meaningful but incomplete response.
2. A 61-year-old woman with recurrent MDD has been stable on lithium augmentation of escitalopram for three years, with a steady-state lithium level of 0.72 mEq/L. Her primary care physician starts ibuprofen 600 mg three times daily for acute low back pain. Ten days later she presents with coarse tremor, vomiting, and confusion. Her serum lithium level is 1.9 mEq/L. Which of the following correctly identifies the mechanism of this interaction and the immediate management priority?
A) Ibuprofen inhibits CYP3A4, the primary hepatic enzyme responsible for lithium clearance, reducing first-pass metabolism and causing lithium accumulation; the immediate priority is administering a CYP3A4 inducer such as rifampin to restore normal lithium clearance
B) Ibuprofen displaces lithium from albumin binding sites, acutely raising the free lithium fraction to toxic concentrations without changing total serum lithium; treatment requires albumin infusion to restore protein binding capacity
C) Ibuprofen alkalinizes urine through carbonic anhydrase inhibition, trapping lithium in the renal tubule through pH-dependent ion exchange; the immediate priority is urinary acidification with ammonium chloride to restore normal lithium excretion
D) Ibuprofen inhibits renal prostaglandin synthesis via COX (cyclooxygenase) inhibition, reducing prostaglandin-dependent renal blood flow and glomerular filtration rate and increasing proximal tubular lithium reabsorption alongside sodium conservation; the immediate priorities are to discontinue ibuprofen, hold lithium, obtain serial lithium levels, provide supportive care, and substitute acetaminophen for analgesia going forward
E) Ibuprofen competitively inhibits the renal organic anion transporter (OAT1) responsible for lithium secretion into the tubular lumen, reducing net renal lithium excretion; activated charcoal should be administered immediately to bind unabsorbed lithium in the gastrointestinal tract
ANSWER: D
Rationale:
Option D is correct. Lithium is eliminated entirely by renal excretion without hepatic metabolism or significant protein binding. In the proximal renal tubule, lithium is handled analogously to sodium — it is reabsorbed alongside sodium via non-selective cation channels. NSAIDs (non-steroidal anti-inflammatory drugs) including ibuprofen inhibit COX (cyclooxygenase) enzymes, suppressing prostaglandin E2 synthesis in the kidney. Prostaglandin E2 normally maintains afferent arteriolar dilation and adequate glomerular filtration rate; its suppression by NSAIDs reduces renal blood flow and GFR (glomerular filtration rate), delivering less sodium — and less lithium — to the distal nephron. Simultaneously, reduced renal perfusion activates compensatory proximal tubular sodium reabsorption, which reabsorbs additional lithium along with sodium. The combined effect is a clinically significant reduction in lithium clearance — studies document 25–60% increases in lithium levels with concurrent NSAID use — sufficient to push this patient's previously therapeutic level of 0.72 mEq/L to a toxic 1.9 mEq/L. The clinical presentation of coarse tremor, vomiting, and confusion is consistent with moderate lithium toxicity. Immediate management requires: discontinuing ibuprofen to remove the precipitating cause; holding lithium until levels return to therapeutic range; serial lithium level monitoring; supportive care including intravenous fluids to maintain renal perfusion and sodium balance; and substituting acetaminophen, which does not inhibit renal prostaglandin synthesis at standard doses, for future analgesia.
Option A: Option A is incorrect because lithium is not metabolized by CYP3A4 or any hepatic enzyme; it has no hepatic first-pass metabolism, and CYP3A4 inducers have no effect on lithium clearance.
Option B: Option B is incorrect because lithium has essentially zero plasma protein binding, making albumin displacement pharmacologically impossible for this drug.
Option C: Option C is incorrect because NSAIDs do not inhibit carbonic anhydrase and do not alkalinize urine; the lithium-NSAID interaction is prostaglandin-mediated, not pH-dependent.
Option E: Option E is incorrect because lithium is not primarily secreted by OAT1 (organic anion transporter 1) — it is reabsorbed alongside sodium in the proximal tubule and does not undergo active tubular secretion; additionally, activated charcoal has minimal efficacy for lithium given that it does not adsorb lithium ions effectively, and the toxicity here is from absorbed drug rather than ongoing gastrointestinal absorption.
3. A 47-year-old woman with three prior depressive episodes — the most recent requiring a brief hospitalization — achieved full remission four months ago on venlafaxine 225 mg. She feels completely well and asks her psychiatrist whether she can now taper and stop the medication. She states she dislikes the idea of taking medication indefinitely. Which of the following represents the most pharmacologically sound and clinically complete response?
A) The psychiatrist should explain that she is currently in the continuation phase — the period of six to twelve months following remission during which early discontinuation carries approximately a 50% relapse rate because the biological substrate of the episode has not yet resolved — and that after completing this phase, the decision whether to enter indefinite maintenance requires weighing her approximately 90% lifetime recurrence risk against the burdens of long-term treatment; the recommendation based on her three-episode history including a severe episode is indefinite maintenance, but this should be presented as a collaborative decision with full disclosure of the recurrence risk of stopping
B) The psychiatrist should agree to begin tapering now, as four months of remission represents adequate continuation phase duration and the patient's strong preference to stop carries significant weight in shared decision-making; a two-week taper is appropriate
C) The psychiatrist should explain that venlafaxine must be continued for exactly twelve months from the date of remission and then can be discontinued without taper, as this fixed duration is the standard guideline for all patients regardless of episode count or severity
D) The psychiatrist should explain that because she has achieved full remission, the antidepressant has completed its neuroplastic mechanism and can be discontinued immediately without relapse risk; the neuroplastic changes are now self-sustaining and independent of continued drug exposure
E) The psychiatrist should explain that discontinuation is not possible for patients who required hospitalization during any prior episode, as hospitalization history is an absolute contraindication to antidepressant discontinuation under current clinical guidelines
ANSWER: A
Rationale:
Option A is correct. Two distinct pharmacological frameworks apply simultaneously to this patient's question, and both must be communicated. First, she is currently only four months into the continuation phase — the six-to-twelve-month period following remission during which the antidepressant is suppressing the manifestation of the biological episode substrate that has not yet resolved on its own timeline. Discontinuing at four months places her squarely within the window of highest relapse risk, where approximately 50% of patients who stop early relapse within six months. The continuation phase must be completed before any taper discussion is appropriate. Second, once the continuation phase is complete, her individual recurrence risk profile determines the maintenance decision: three prior episodes place her lifetime recurrence probability at approximately 90% without maintenance therapy, and a prior hospitalization indicates episode severity that independently supports indefinite maintenance. Guideline-based recommendations for her are clear — indefinite maintenance is indicated — but the pharmacologist's communication responsibility is to present this evidence clearly and collaboratively rather than directively, respecting her autonomy to weigh the approximately 90% recurrence risk against her preference to stop.
Option B: Option B is incorrect because four months does not complete the continuation phase, and a two-week taper after only four months of post-remission treatment exposes the patient to the highest-risk window for relapse; her preference, while valid, does not override the pharmacological evidence for continuation phase completion.
Option C: Option C is incorrect because twelve months is not a fixed standard for all patients regardless of episode count; continuation phase guidance (six to twelve months) transitions to individualized maintenance decisions based on recurrence risk profile, not a universal fixed-duration rule.
Option D: Option D is incorrect because the neuroplastic changes supporting remission are not permanently self-sustaining; BDNF expression, synaptic remodeling, and HPA normalization partially reverse when the antidepressant is withdrawn, which is precisely why premature discontinuation causes relapse at the rates observed.
Option E: Option E is incorrect because prior hospitalization is not an absolute contraindication to eventual antidepressant discontinuation; it is a clinical risk factor that increases the strength of the recommendation for indefinite maintenance but does not make discontinuation an absolute prohibition under any guideline.
4. A 41-year-old man has been treated for recurrent MDD for eight years. He has been on fluoxetine for six months with initial improvement followed by a return of depressive symptoms, increased irritability, and what he describes as "two or three days each month where I feel wired, don't need sleep, and can't stop talking." He reports this pattern of short high-energy periods has been present intermittently since his mid-twenties but was never mentioned to previous providers. His MDQ (Mood Disorder Questionnaire) score is positive. Which of the following correctly identifies what has been occurring and the required pharmacological change?
A) This pattern represents the expected fluctuating course of treatment-resistant unipolar depression; the brief high-energy periods are residual symptoms of MDD rather than hypomania, and the correct response is to increase fluoxetine to the maximum labeled dose to achieve more complete monoaminergic suppression of the mood cycling
B) The brief high-energy periods represent fluoxetine-induced akathisia — a sense of inner restlessness and driven behavior caused by excessive serotonergic activation — rather than true hypomania; the correct response is to add a beta-blocker to suppress the akathisia while continuing fluoxetine unchanged
C) The history is consistent with bipolar II disorder in which fluoxetine monotherapy has likely contributed to mood destabilization through excessive monoaminergic drive on a cycling substrate; the required pharmacological pivot is to discontinue fluoxetine monotherapy and initiate a mood stabilizer with established efficacy in bipolar II depression — such as lamotrigine, lithium, quetiapine, or lurasidone — as the primary treatment goal, using antidepressants only as an adjunct to mood stabilization if needed under close monitoring
D) This pattern confirms serotonin syndrome from long-term fluoxetine exposure; the brief hyperstimulation periods represent intermittent serotonin excess, and the correct response is to switch to a non-serotonergic antidepressant such as bupropion while monitoring serotonin metabolite levels
E) The brief high-energy periods represent normal variation within unipolar MDD that does not require diagnostic reassessment; the correct pharmacological response is to add a sedating antihistamine such as hydroxyzine on the days of high energy to blunt the stimulation without altering the antidepressant regimen
ANSWER: C
Rationale:
Option C is correct. The clinical pattern described — recurrent depressive episodes with apparent antidepressant treatment failure, mood instability on antidepressants, and discrete periods of reduced sleep need, elevated energy, pressured speech, and driven behavior lasting two to three days recurring monthly — is consistent with bipolar II disorder. The brief hypomanic periods are classic: in bipolar II, hypomanic episodes are frequently mild, short, and ego-syntonic (experienced as productive rather than abnormal), which is why they are not spontaneously reported and go undetected for years. A positive MDQ adds structured evidence. Fluoxetine monotherapy in this context has likely contributed to cycle acceleration — the increase in frequency of mood episodes that antidepressants can produce in bipolar disorder through excessive monoaminergic stimulation of an already sensitized cycling substrate. The required pharmacological pivot is to discontinue antidepressant monotherapy, which is no longer appropriate as the primary treatment, and initiate mood stabilization. Lamotrigine has specific evidence for bipolar II depressive episodes and is often the first-choice mood stabilizer in this context; lithium, quetiapine, and lurasidone also have evidence for bipolar II depression. If antidepressant augmentation is considered after mood stabilization is established, it must be used cautiously as an adjunct to a mood stabilizer rather than as monotherapy.
Option A: Option A is incorrect because brief discrete periods of reduced sleep need, elevated energy, and pressured speech in the context of a cycling mood disorder and a positive MDQ are not residual MDD symptoms; they meet criteria for hypomanic episodes, and increasing fluoxetine would worsen cycle acceleration.
Option B: Option B is incorrect because akathisia is a subjective sense of inner restlessness and motor-driven behavior that is continuous rather than episodic, does not involve reduced sleep need or mood elevation, and does not present as discrete days of heightened productivity with reduced sleep; the described pattern is not akathisia.
Option D: Option D is incorrect because serotonin syndrome is an acute, potentially life-threatening pharmacological toxidrome characterized by hyperthermia, clonus, hyperreflexia, and autonomic instability — not intermittent monthly mood elevation periods of years' duration; the longitudinal episodic pattern described is not consistent with serotonin syndrome.
Option E: Option E is incorrect because the described pattern warrants explicit diagnostic reassessment for bipolar spectrum illness, not pharmacological symptom suppression without reconsidering the primary diagnosis; treating unrecognized bipolar II with continued antidepressant monotherapy plus a sedative risks worsening the underlying mood cycling trajectory.
5. A 68-year-old man with severe TRD and a prior suicide attempt is receiving ECT (electroconvulsive therapy). After his fifth treatment session, his wife reports that he is confused about recent events, cannot recall their daughter's wedding two months ago, and is struggling to retain new information from day to day. She asks: "Is this permanent? Has ECT damaged his brain?" Which of the following represents the most accurate and complete response?
A) The cognitive effects she is describing are permanent; ECT produces irreversible hippocampal damage through repeated seizure-induced excitotoxicity, and the memory impairment will not recover — this risk should have been disclosed during the informed consent process before the first treatment
B) The cognitive effects are entirely due to the anesthetic agents used during ECT rather than the electrical stimulus itself; switching to a different anesthetic agent will immediately resolve the memory impairment without interrupting the treatment course
C) The memory difficulties indicate that ECT has been administered at an excessive dose; the treatment should be stopped immediately and restarted at the minimum effective stimulus intensity after a two-week washout period to prevent further hippocampal injury
D) The cognitive effects she is describing are caused by the underlying depression rather than ECT; severe depression itself causes anterograde and retrograde amnesia that resolves with successful antidepressant treatment, and ECT is not contributing to the memory difficulties
E) The effects she is describing — anterograde amnesia (difficulty forming new memories) and retrograde amnesia (loss of memories from the period around treatment) — are expected and well-documented cognitive adverse effects of ECT that are most prominent during the acute treatment course; the majority of patients experience substantial recovery of these effects within weeks to months of completing ECT, and most cognitive effects resolve fully within six months, though some patients retain gaps in autobiographical memory from the period around treatment; the treating team should discuss these facts with her and consider electrode placement or stimulus parameter adjustments to minimize cognitive burden if clinically appropriate
ANSWER: E
Rationale:
Option E is correct. The cognitive effects described — confusion about recent events, loss of memory for events shortly before treatment began, and difficulty forming and retaining new memories during the treatment course — are the expected anterograde and retrograde amnestic effects of ECT, most pronounced during and immediately following the acute treatment course. These are among the best-characterized adverse effects of ECT and are part of the standard informed consent discussion before treatment. The reassuring evidence is that the majority of patients experience meaningful recovery of these cognitive effects within weeks to months of completing ECT, and most cognitive effects resolve fully within six months of treatment completion. Some patients do retain persistent gaps in autobiographical memory specifically for events close in time to the treatment course — an important caveat that should be communicated honestly. The clinical response in this patient should include an honest and supportive conversation with his wife about the expected time course of recovery, and a clinical discussion about whether electrode placement modifications (right unilateral rather than bilateral placement reduces anterograde amnesia) or stimulus parameter changes (ultra-brief pulse reduces cognitive effects compared to standard brief pulse) are appropriate given his clinical response to the current course. Given his severe TRD and prior suicidality, abrupt discontinuation of ECT would carry significant clinical risk and must be weighed carefully.
Option A: Option A is incorrect because ECT does not produce irreversible hippocampal damage from excitotoxicity in standard clinical practice; decades of neuroimaging follow-up studies have not demonstrated permanent structural brain injury from therapeutic ECT, and characterizing the effects as irreversible would cause unnecessary harm to this family.
Option B: Option B is incorrect because while the anesthetic agents contribute to peri-session confusion, the anterograde and retrograde amnesia developing across an ECT course are attributable to the electrical stimulus and cumulative seizure-driven neurophysiological effects, not solely to the anesthetics; changing the anesthetic agent will not resolve these effects.
Option C: Option C is incorrect because the described cognitive effects during a standard ECT course do not require immediate discontinuation and a two-week washout; this response would interrupt clinically necessary treatment in a patient with severe TRD and prior suicidality based on expected adverse effects that warrant monitoring and potential parameter adjustment, not emergency cessation.
Option D: Option D is incorrect because while depression does impair memory and cognition, the pattern of worsening anterograde and retrograde amnesia developing progressively across an ECT course — particularly the loss of memories from the period immediately preceding treatment — is characteristic of ECT-associated cognitive effects rather than depression alone; attributing all cognitive effects to the underlying illness is clinically inaccurate and fails to provide the family with truthful information.
6. A 55-year-old woman with MDD has been on escitalopram 20 mg for twelve weeks with good improvement in depressed mood, anhedonia, and social withdrawal. However, she continues to experience significant difficulty falling asleep, frequent nighttime awakening with anxious rumination, and moderate daytime anxiety. She denies fatigue, cognitive difficulties, or motivational problems. Which of the following augmentation strategies is most pharmacologically appropriate for her specific residual symptom profile, and what is the mechanistic basis for that choice?
A) Add bupropion 150 mg daily, because its NET (norepinephrine reuptake transporter) and DAT (dopamine reuptake transporter) inhibition will address the noradrenergic and dopaminergic deficits underlying her insomnia and anxiety through enhanced prefrontal monoaminergic tone
B) Add quetiapine 50–100 mg at bedtime, because its potent H1 (histamine type 1 receptor) antagonism produces sedation and sleep-onset facilitation addressing her insomnia, and its 5-HT2A antagonism combined with partial 5-HT1A agonism provides anxiolytic activity that directly targets her nighttime anxiety and rumination — mechanistically filling the gaps that escitalopram's serotonin-selective mechanism does not adequately address for these specific symptom dimensions
C) Add lithium 300 mg twice daily, because its inhibition of inositol monophosphatase and potentiation of serotonergic second-messenger signaling will amplify escitalopram's serotonergic mechanism and thereby resolve both the insomnia and anxiety as downstream consequences of enhanced serotonergic neurotransmission
D) Add aripiprazole 5 mg daily, because its D2 partial agonism and 5-HT2A antagonism have the broadest evidence base for SSRI augmentation and should be considered before any other augmentation agent in any patient with residual symptoms on an SSRI
E) Add a benzodiazepine such as clonazepam 0.5 mg at bedtime, because benzodiazepines are the most pharmacologically direct treatment for anxiety and insomnia and should be the first augmentation choice in patients with these specific residual symptoms before atypical antipsychotics are considered
ANSWER: B
Rationale:
Option B is correct. This patient's residual symptom profile — insomnia, nighttime anxiety, and anxious rumination without fatigue or motivational deficits — maps precisely onto the pharmacological strengths of quetiapine at low augmentation doses. Quetiapine's potent H1 receptor antagonism (among the highest affinity of any drug in clinical use) produces reliable sedation and sleep-onset facilitation that directly addresses her insomnia and interrupted sleep. Its 5-HT2A receptor antagonism disinhibits noradrenergic and dopaminergic release in the prefrontal cortex with downstream anxiolytic effects, and its partial 5-HT1A agonism adds a direct anxiolytic mechanism analogous to buspirone that specifically targets the anxiety and rumination dimensions of her residual profile. Administering quetiapine at bedtime aligns the peak pharmacological effect of the H1 blockade with the time of the patient's most troublesome symptoms, minimizing daytime sedation. This is a textbook application of the pharmacological gap principle: quetiapine fills the specific receptor dimensions — H1 sedation, 5-HT2A and 5-HT1A anxiolysis — that escitalopram's transporter-blocking mechanism cannot address.
Option A: Option A is incorrect because bupropion's NET/DAT inhibition increases noradrenergic and dopaminergic tone — a mechanism that would be expected to worsen anxiety and insomnia rather than treat them; bupropion is the pharmacologically appropriate choice for fatigue, anhedonia, and cognitive slowing, not for the anxiety and insomnia profile this patient presents.
Option C: Option C is incorrect because lithium's augmentation mechanism is serotonergic second-messenger potentiation; while this may deepen the overall antidepressant response, it does not specifically address the H1-mediated insomnia or the direct receptor-level anxiolytic gaps that quetiapine fills, and lithium requires renal monitoring that adds clinical burden relative to this patient's symptom profile.
Option D: Option D is incorrect because the pharmacological gap framework calls for matching the agent to the specific residual symptom dimensions; while aripiprazole has broad augmentation evidence, its pharmacological profile does not include the H1 sedation or the 5-HT1A anxiolysis that make quetiapine specifically suited to this patient's insomnia and anxiety.
Option E: Option E is incorrect because benzodiazepines, while effective for acute anxiety and insomnia, carry risks of physical dependence, withdrawal syndrome, and cognitive impairment that make them suboptimal for long-term maintenance augmentation in a patient whose residual symptoms exist in the context of ongoing antidepressant therapy; quetiapine provides equivalent or superior coverage for both target symptoms without dependence risk.
7. A 49-year-old woman with apparent TRD has failed two adequate antidepressant trials — sertraline and venlafaxine — each at therapeutic doses for eight weeks without meaningful response. Routine laboratory screening reveals a TSH (thyroid-stimulating hormone) of 4.8 mIU/L with a normal reference range of 0.4–4.0 mIU/L, and a normal free T4. She has no symptoms she attributes to thyroid disease. Which of the following best describes the pharmacological significance of this finding and the appropriate next step?
A) A TSH of 4.8 mIU/L is only marginally above the upper reference limit and is clinically insignificant; subclinical hypothyroidism at this level has no established effect on antidepressant response, and the next step is to proceed directly to a third antidepressant trial
B) The elevated TSH confirms overt hypothyroidism requiring immediate high-dose levothyroxine replacement; subclinical hypothyroidism at this level causes irreversible neuronal damage that will prevent future antidepressant response unless thyroid replacement is started within two weeks
C) The elevated TSH indicates hyperthyroidism from TSH-secreting pituitary adenoma; the elevated TSH is driving excessive thyroid hormone production and causing a hyperadrenergic state that mimics depression while blocking antidepressant receptor binding
D) A TSH of 4.8 mIU/L above the upper normal limit defines subclinical hypothyroidism — a reversible medical condition that impairs central serotonergic and noradrenergic receptor sensitivity and can prevent adequate antidepressant response regardless of drug selection or dose; this represents pseudo-resistance rather than true pharmacological TRD, and the appropriate next step is to treat the subclinical hypothyroidism with levothyroxine and reassess antidepressant response before concluding treatment resistance
E) The elevated TSH is a pharmacokinetic finding indicating that venlafaxine and sertraline have been inducing thyroid hormone metabolism through CYP enzyme activation; discontinuing the antidepressants will restore normal TSH within two weeks and antidepressant therapy can then be restarted at higher doses
ANSWER: D
Rationale:
Option D is correct. A TSH above the upper limit of the normal reference range (4.0 mIU/L in most laboratories) with a normal free T4 defines subclinical hypothyroidism — a condition in which the pituitary gland is producing elevated TSH to drive adequate thyroid hormone output, indicating that the thyroid gland requires additional stimulation to maintain normal circulating thyroid hormone levels. Even without overt clinical hypothyroid symptoms, subclinical hypothyroidism impairs the neurobiological substrates of antidepressant action: thyroid hormone regulates central serotonergic and noradrenergic receptor sensitivity through nuclear receptor-mediated gene expression in neurons, and even borderline-low thyroid hormone signaling can reduce the responsiveness of these systems to antidepressant drug effects. This constitutes pseudo-resistance — apparent pharmacological treatment failure caused by a reversible medical condition rather than true refractoriness to the antidepressant mechanism. Before labeling this patient as having TRD and proceeding to more intensive interventions, the appropriate next step is to initiate levothyroxine therapy to normalize TSH and then reassess antidepressant response; some patients achieve full remission on a previously ineffective antidepressant once thyroid function is optimized.
Option A: Option A is incorrect because subclinical hypothyroidism at this level does have an established association with antidepressant non-response in the psychiatric and endocrinology literature; dismissing it as clinically insignificant before correction is a missed opportunity to address a reversible cause of pseudo-resistance.
Option B: Option B is incorrect because subclinical hypothyroidism does not cause irreversible neuronal damage, and the urgency described — requiring treatment within two weeks to prevent permanent injury — is not supported by evidence; while treatment is indicated, the framing of irreversible injury is inaccurate.
Option C: Option C is incorrect because an elevated TSH indicates that the pituitary is working harder to stimulate a relatively underperforming thyroid — the opposite of hyperthyroidism; in primary hyperthyroidism, TSH is suppressed (low), not elevated, as the pituitary reduces its drive in response to excessive circulating thyroid hormone.
Option E: Option E is incorrect because sertraline and venlafaxine do not induce thyroid hormone metabolism through CYP enzymes in a way that causes sustained TSH elevation; CYP-mediated drug interactions do not produce the pattern of subclinical hypothyroidism described here, and discontinuing the antidepressants would not restore TSH by this mechanism.
8. A 34-year-old man has had an inadequate response to one adequate trial of escitalopram for MDD. His psychiatrist recommends a course of rTMS (repetitive transcranial magnetic stimulation). The patient asks: "Why not go straight to ECT (electroconvulsive therapy)? I've heard it's more effective." Which of the following most accurately addresses his question?
A) rTMS is FDA-cleared for MDD after failure of one adequate antidepressant trial, making it an appropriate option at this stage; ECT is generally reserved for more advanced treatment resistance — typically patients who have failed multiple pharmacological steps — and for presentations requiring urgent response such as psychotic depression, severe suicidality, or inability to eat or drink; at one failed trial, the patient has not yet reached the treatment resistance threshold where ECT's cognitive adverse effects, anesthesia requirement, and procedural intensity are proportionate to his clinical situation
B) ECT is contraindicated in patients under age 40 because the seizure-induced neurotrophic response produces excessive hippocampal neurogenesis in younger brains that can paradoxically worsen depressive symptoms; rTMS is used in younger patients precisely because it avoids this age-dependent adverse neuroplastic effect
C) rTMS and ECT are equivalent in efficacy for all stages of MDD, so the choice between them is made purely on patient convenience; rTMS is recommended first because it requires fewer clinic visits and has a shorter treatment course than ECT
D) ECT requires a minimum of five failed antidepressant trials before it can be offered under current FDA guidelines; rTMS is the only somatic intervention cleared for use after a single treatment failure
E) ECT is more effective than rTMS but is not available as an outpatient procedure at most centers; the recommendation for rTMS reflects logistical unavailability of ECT rather than a clinical judgment about which intervention is more appropriate at this stage of treatment resistance
ANSWER: A
Rationale:
Option A is correct. The FDA-cleared indication for rTMS in MDD requires failure of at least one adequate antidepressant trial — a deliberately low treatment resistance threshold that positions rTMS early in the treatment algorithm, accessible before the patient has exhausted multiple pharmacological strategies. ECT, by contrast, is not regulated by the same single-failed-trial threshold; it is reserved in clinical practice for patients with more advanced pharmacological treatment failure, or specifically for presentations where its superior efficacy and speed of response are medically necessary — severe depression with psychotic features, imminent suicidal risk, refusal to eat or drink, or pregnancy where pharmacological alternatives are problematic. The rationale for this clinical staging is proportionality: ECT requires general anesthesia, produces anterograde and retrograde amnesia during the acute course, and carries the procedural burden of hospital-based treatment — adverse effects and logistical demands that are disproportionate for a patient who has failed only one antidepressant trial and whose depression, while requiring treatment, does not constitute an emergency. rTMS offers meaningful efficacy without anesthesia, without significant cognitive adverse effects, and in an outpatient setting, making it proportionate to the patient's current treatment resistance stage. As treatment resistance deepens — with more failed pharmacological steps, increasing severity, or urgent clinical features — the benefit-risk calculation shifts in favor of ECT's more robust but more burdensome intervention.
Option B: Option B is incorrect because ECT is not contraindicated in patients under 40; age-based restrictions on ECT are not part of evidence-based guidelines, and excessive hippocampal neurogenesis in younger patients is not an established or clinically meaningful adverse effect of ECT.
Option C: Option C is incorrect because rTMS and ECT are not equivalent in efficacy across all stages of MDD; ECT produces substantially higher remission rates (50–70%) than rTMS (30–37%) in treatment-resistant populations, and the choice between them is driven by clinical stage and indication, not convenience.
Option D: Option D is incorrect because the FDA has not established a five-failed-trial minimum for ECT; ECT is not subject to an FDA-mandated trial threshold in the same regulatory framework as device clearance, and clinical guidelines do not require five failed trials before ECT is appropriate.
Option E: Option E is incorrect because the recommendation for rTMS reflects a genuine clinical judgment about treatment resistance staging and proportionality, not simply logistical unavailability of ECT; framing the recommendation as a logistical compromise misrepresents the clinical reasoning.
9. A 31-year-old woman has failed three sequential antidepressant trials — paroxetine, fluoxetine, and nortriptyline — each at standard doses for eight weeks with no clinical response and, notably, no adverse effects at any dose. Pharmacogenomic testing reveals CYP2D6 (cytochrome P450 2D6 enzyme) ultra-rapid metabolizer genotype. Review of her medication history confirms that all three drugs she received are primarily metabolized by CYP2D6. Which of the following represents the most pharmacologically rational next treatment step?
A) Add lithium augmentation to a fourth trial of a CYP2D6-substrate antidepressant, because the combination of augmentation and a serotonergic antidepressant will overcome the pharmacokinetic limitation by activating alternative downstream pathways that do not require adequate plasma drug concentration
B) Refer for ECT as the next treatment step, because pharmacogenomic pseudo-resistance from CYP2D6 ultra-rapid metabolizer status constitutes true TRD and indicates that pharmacological treatment will never achieve adequate drug exposure regardless of agent selection
C) Switch to an antidepressant not primarily metabolized by CYP2D6 — such as escitalopram (primarily CYP2C19), citalopram (primarily CYP2C19), or venlafaxine (which achieves active plasma concentrations across metabolizer phenotypes) — at standard doses; the prior failures represent pharmacokinetic pseudo-resistance from subtherapeutic drug exposure rather than true pharmacological refractoriness, and a CYP2D6-independent agent should be given a full adequate trial before any more intensive intervention is considered
D) Continue with a CYP2D6-substrate antidepressant but increase the dose to four times the standard labeled dose to overcome the ultra-rapid metabolism; plasma level monitoring is not necessary because ultra-rapid metabolizers tolerate higher doses without adverse effects
E) Switch to an MAOI (monoamine oxidase inhibitor) as the only class of antidepressant with a pharmacokinetic profile completely independent of all CYP enzymes; MAOIs are the definitive pharmacological solution for CYP2D6 ultra-rapid metabolizers with apparent treatment resistance
ANSWER: C
Rationale:
Option C is correct. The clinical reasoning is straightforward once the pharmacogenomic cause of pseudo-resistance is identified. All three prior antidepressant trials failed because CYP2D6 ultra-rapid metabolizer genotype caused the drugs — paroxetine, fluoxetine, and nortriptyline, all of which are CYP2D6 substrates — to be eliminated so rapidly that plasma concentrations never reached the therapeutic range at standard doses. This is pharmacokinetic pseudo-resistance: the antidepressant mechanism was never engaged at the cellular level because the drug was cleared before it could achieve adequate target tissue exposure. The solution is a pharmacokinetic pivot — switching to an antidepressant whose primary metabolic pathway does not involve CYP2D6. Escitalopram and citalopram are metabolized primarily by CYP2C19 and CYP3A4 with minimal CYP2D6 involvement; in CYP2D6 ultra-rapid metabolizers, these drugs achieve standard therapeutic plasma concentrations because their elimination is not accelerated by the dysfunctional CYP2D6. Venlafaxine is partially metabolized by CYP2D6 to O-desmethylvenlafaxine, but both the parent compound and the metabolite are pharmacologically active, and therapeutic efficacy is maintained across metabolizer phenotypes. Any of these agents should be given a full adequate trial at standard doses before considering more intensive interventions such as augmentation strategies or somatic treatments.
Option A: Option A is incorrect because adding lithium augmentation to a drug that cannot achieve therapeutic plasma concentrations does not resolve the pharmacokinetic limitation; augmenting a subtherapeutic antidepressant level does not substitute for the primary drug's pharmacological effect.
Option B: Option B is incorrect because CYP2D6 ultra-rapid metabolizer pseudo-resistance is entirely correctable by switching to a CYP2D6-independent agent; ECT referral without first attempting a pharmacokinetically appropriate antidepressant trial is a premature escalation that does not address the identified cause of treatment failure.
Option D: Option D is incorrect because empirically escalating CYP2D6-substrate antidepressants to four times standard doses without plasma level guidance risks serious adverse effects and toxicity; while dose escalation with therapeutic drug monitoring is one option, it requires careful pharmacokinetic monitoring, not empiric quadrupling, and switching to a non-CYP2D6 substrate is a simpler and safer approach.
Option E: Option E is incorrect because MAOIs are not the definitive solution for CYP2D6 ultra-rapid metabolizers; while some MAOIs have CYP2D6-independent elimination, MAOIs carry significant dietary tyramine interaction risks, dangerous drug interactions, and clinical complexity that make them a last-resort option rather than the appropriate next step when simpler CYP2D6-independent agents are available.
10. A 52-year-old woman achieved remission at STAR*D Step 2 on citalopram plus bupropion augmentation after failing citalopram alone at Step 1. She has been in full remission for three months. Her psychiatrist considers stopping bupropion now to simplify her regimen, reasoning that citalopram alone was partially effective and may be sufficient to maintain remission now that it has been achieved. Which of the following best evaluates this reasoning?
A) The reasoning is correct; once remission is achieved with augmentation, the augmenting agent can be discontinued after three months because the remission itself reflects restored neuroplasticity that is now self-sustaining and independent of the bupropion component
B) The reasoning is correct; bupropion should be tapered over four weeks and citalopram continued at the same dose, because the combination was required only to achieve remission — the natural history of MDD predicts that remission is self-sustaining once established regardless of which drugs produced it
C) The reasoning is partially correct; bupropion can be stopped but citalopram should be increased to the maximum dose to compensate for the loss of noradrenergic and dopaminergic coverage, as higher serotonin reuptake blockade will substitute for the NET and DAT inhibition provided by bupropion
D) The reasoning is incorrect because discontinuing bupropion requires a mandatory six-month washout period before any changes to the citalopram dose can be made; the washout prevents receptor rebound that could precipitate a severe depressive relapse
E) The reasoning is flawed; the same pharmacological principle governing antidepressant continuation applies to the augmenting agent — the combination that produced remission should be maintained at the same doses throughout the continuation phase, because removing bupropion reintroduces the pharmacological gap in noradrenergic and dopaminergic coverage that prevented citalopram monotherapy from achieving remission at Step 1, and three months post-remission is still within the continuation window where early pharmacological changes carry significant relapse risk
ANSWER: E
Rationale:
Option E is correct. The continuation phase principle — maintain the regimen that produced remission at the same doses for six to twelve months — applies to the complete treatment regimen, not only to the primary antidepressant. The pharmacological argument for discontinuing bupropion after three months of remission contains a logical flaw: citalopram alone was inadequate to produce remission at Step 1 precisely because it could not address the noradrenergic and dopaminergic deficits that bupropion's NET and DAT inhibition covers. Remission was achieved specifically because the combination filled that pharmacological gap. Removing bupropion three months into the continuation phase reintroduces the exact pharmacological insufficiency that produced treatment failure on citalopram monotherapy, while simultaneously placing the patient in the highest-risk period for relapse — the first six months after remission. The neuroplastic changes supporting remission depend on the continued pharmacological environment that produced them; they are not independently sustained by remission itself. Clinical evidence for augmentation strategies consistently shows that discontinuing the augmenting agent before completing the continuation phase increases relapse risk. The appropriate approach is to maintain the full combination regimen through the continuation phase and then make individualized decisions about maintenance phase regimen simplification based on recurrence risk and patient preference.
Option A: Option A is incorrect because remission does not represent a pharmacologically self-sustaining neuroplastic state; the BDNF upregulation, synaptic remodeling, and HPA normalization supporting remission require continued drug exposure at adequate concentrations to be maintained, as evidenced by the relapse rates when drugs are withdrawn in the continuation phase.
Option B: Option B is incorrect for the same mechanistic reason: remission is not inherently self-sustaining regardless of which drugs produced it, and the natural history of MDD in the absence of pharmacological maintenance shows approximately 50% relapse rates within six months of discontinuation during the continuation window.
Option C: Option C is incorrect because increasing serotonin reuptake blockade does not substitute for NET and DAT inhibition; the neurotransmitter systems involved are pharmacologically distinct, and more serotonergic activity does not compensate for reduced noradrenergic and dopaminergic coverage.
Option D: Option D is incorrect because there is no pharmacological requirement for a six-month washout between stopping bupropion and adjusting citalopram; this invented washout requirement has no mechanistic basis and is not a clinical guideline recommendation.
11. A 45-year-old man with MDD has failed two adequate SSRI trials — sertraline and escitalopram — with minimal response to either. Routine laboratory screening reveals CRP (C-reactive protein) of 5.2 mg/L (reference range less than 3.0 mg/L) in the absence of any identified acute infection, inflammatory disease, or other medical cause. His TSH, renal function, and CBC (complete blood count) are normal. Which of the following best describes the pharmacological significance of this finding and how it should influence the next treatment decision?
A) An elevated CRP confirms systemic infection as the cause of treatment resistance; antidepressants are ineffective in the setting of active infection and should be discontinued until a course of empiric antibiotics resolves the elevated inflammatory marker
B) A CRP above 3 mg/L in the absence of acute illness identifies a patient whose MDD may have a neuroinflammatory biological substrate; this inflammatory subtype is associated with poor SSRI response — likely through cytokine-mediated suppression of BDNF (brain-derived neurotrophic factor) expression, impaired hippocampal neurogenesis, HPA (hypothalamic-pituitary-adrenal) axis dysregulation, and tryptophan metabolism disruption via the kynurenine pathway — and may predict relatively better response to antidepressants with anti-inflammatory properties or to bupropion; this information should guide the selection of the next antidepressant rather than defaulting to a third SSRI trial
C) An elevated CRP at this level indicates that the patient is a CYP2D6 ultra-rapid metabolizer; CRP is a pharmacogenomic marker for CYP enzyme activity, and the appropriate response is to order formal CYP2D6 genotyping before selecting the next antidepressant
D) The elevated CRP confirms that this patient has TRD by satisfying the inflammatory biomarker criterion required for formal TRD diagnosis; esketamine is now mandated as the next treatment step based on FDA approval criteria for the neuroinflammatory TRD subtype
E) The elevated CRP is clinically irrelevant to antidepressant selection; CRP reflects cardiovascular risk rather than neurobiological antidepressant response mechanisms, and the next step is simply to proceed to a third antidepressant trial from a different class without considering the inflammatory finding
ANSWER: B
Rationale:
Option B is correct. A CRP above 3 mg/L in the absence of acute illness or identified inflammatory disease represents chronic low-grade systemic inflammation that is increasingly recognized as a biological marker of a neuroinflammatory subtype of MDD. The mechanistic chain linking elevated CRP to antidepressant resistance is multifactorial: pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha, which are co-elevated with CRP in this inflammatory state, suppress BDNF expression in hippocampal neurons — reducing the neuroplastic substrate that antidepressants depend on for their efficacy; they inhibit hippocampal neurogenesis; they activate and dysregulate the HPA axis driving hypercortisolemia; and they activate indoleamine 2,3-dioxygenase (IDO) in the kynurenine pathway, diverting tryptophan away from serotonin synthesis and toward potentially neurotoxic kynurenine metabolites — directly reducing serotonin availability and SSRI pharmacological substrate. The clinical implication is that patients with this inflammatory MDD subtype may have a biologically grounded reason for poor SSRI response, and that switching to a third SSRI trial without addressing the inflammatory context is unlikely to improve outcomes. Evidence suggests these patients may respond better to antidepressants with anti-inflammatory properties or to bupropion, which has some evidence of preferential efficacy in high-CRP MDD; more intensive somatic interventions should also be considered. While inflammatory biomarker-guided treatment selection is not yet a standard clinical algorithm, the finding at minimum should influence the next drug choice rather than be disregarded.
Option A: Option A is incorrect because a CRP of 5.2 mg/L in a patient without identified infection or inflammatory disease represents low-grade chronic inflammation rather than acute infection; empiric antibiotics are not indicated and would not address the neurobiological consequences of chronic neuroinflammation.
Option C: Option C is incorrect because CRP is an acute-phase reactant reflecting inflammatory status — it is not a pharmacogenomic marker for CYP2D6 activity or any CYP enzyme; the two biomarker types are entirely unrelated.
Option D: Option D is incorrect because elevated CRP is not an FDA-required biomarker criterion for TRD diagnosis or esketamine indication; the FDA approval of esketamine for TRD is based on pharmacological trial failure criteria, not inflammatory biomarker levels, and no mandated treatment pathway based solely on CRP exists.
Option E: Option E is incorrect because the growing body of evidence linking elevated CRP to poor SSRI response and potentially differential response to other agents makes this finding clinically actionable in antidepressant selection; dismissing it as relevant only to cardiovascular risk misrepresents the pharmacological literature on inflammatory MDD subtypes.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.